CDKN2B and adrenal cortex carcinoma: Moreover, through prognostic analysis of tumour diseases, we found that patients with high expression of CDKN2B-AS1 in LC, adrenocortical carcinoma, and renal clear cell carcinoma generally have a lower prognostic survival rate (Figure 3(b)).